Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial

Breast Cancer Research and Treatment

Volumn 126, Issue 3, 2011, Pages 643-651

  Gluz, Oleg ^b,h   Wild, Peter ^a,e   Liedtke, Cornelia ^b,d   Kates, Ronald ^b   Mendrik, Heiko ^a   Ehm, Elisabeth ^a   Artinger, Verena ^a   Diallo Danebrock, Raihanatou ^c   Ting, Evelyn ^c   Mohrmann, Svjetlana ^c   Poremba, Christopher ^c,g   Harbeck, Nadia ^j   Nitz, Ulrike ^b,c   Hartmann, Arndt ^a,f   Gaumann, Andreas ^a,i  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b West German Study Group   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g Institute of Histopathology   (Germany)

^h Bethesda Clinics Wuppertal   (Germany)

ⁱ Institute of Pathology   (Germany)

^j UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

Angiogenesis; High dose chemotherapy; High risk breast cancer; Immunohistochemistry; Molecular subtypes

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; ENDOGLIN;

ADULT; ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLUSTER ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EVENT FREE SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; ANTIGENS, CD; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLUSTER ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MARKERS, BIOLOGICAL;

EID: 79958716116     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1377-6     Document Type: Article

References (45)

1. Fisher B, Bauer M, Wickerham D et al (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52(9): 1551-1557 (Pubitemid 13018271)
2. Gluz O, Nitz UA, Harbeck N et al (2008) Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 19(5):861-870 (Pubitemid 351649186)
3. Kroger N, Milde-Langosch K, Riethdorf S et al (2006) Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12(1): 159-168 (Pubitemid 43166190)
4. Faneyte IF, Peterse JL, Van Tinteren H et al (2004) Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 10(13):4457-4463 (Pubitemid 38878889)
5. Nitz U, Mohrmann S, Fischer J et al (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366(9501):1935-1944 (Pubitemid 41713983)
6. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
7. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98(19):10869-10874 (Pubitemid 32878711)
8. Diallo-Danebrock R, Ting E, Gluz O et al (2007) Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy. Clin Cancer Res 13(2):488-497 (Pubitemid 46225354)
9. Hannemann J, Hannemann J, Kristel P et al (2006) Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer 95(10):1334-1341 (Pubitemid 44760082)
10. Gluz O, Mengele K, Schmitt M et al (2009) Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 27(36):6144-6151
11. Gasparini G, Weidner N, Bevilacqua P et al (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12(3):454-466 (Pubitemid 24079885)
12. Heimann R, Ferguson D, Powers C et al (1996) Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88(23):1764-1769 (Pubitemid 26405014)
13. Uzzan B, Nicolas P, Cucherat M et al (2004) Microvessel density as a prognostic factor in women with breast cancer. Cancer Res 64(9):2941-2955
14. Kumar S, Ghellal A, Li C et al (1999) Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59(4):856-861 (Pubitemid 29086739)
15. Bodey B, Bodey BJ, Siegel S et al (1998) Over-expression of endoglin (CD105): a marker of breast carcinoma-induced neovascularization. Anticancer Res 18(5A):3621-3628 (Pubitemid 28546500)
16. Dallas NA, Samuel S, Xia L et al (2008) Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res 14(7):1931-1937 (Pubitemid 351551101)
17. Li C, Gardy R, Seon BK et al (2003) Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88(9):1424-1431 (Pubitemid 36606427)
18. Fujita KC, Ewing MD, Chan YS et al (2009) Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 124(3):664-669
19. Yao Y, Kubota T, Takeuchi H et al (2005) Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology 25(3): 201-206 (Pubitemid 41602604)
20. Nieto Y, Woods J, Nawaz F et al (2007) Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 97(3):391
21. Vermeulen P, Gasparini G, Fox S et al (1996) Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32(14):2474-2484
22. Vermeulen PB, Gasparini G, Fox SB et al (2002) Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38(12):1564-1579 (Pubitemid 34876495)
23. Weidner N, Semple J, Welch W et al (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324(1):1-8
24. McShane LM, Altman DG, Sauerbrei W et al (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16):1180-1184 (Pubitemid 41258223)
25. Shipitsin M, Campbell L, Argani P et al (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259-273 (Pubitemid 46349843)
26. de Caestecker MP, Piek E, Roberts AB (2000) Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92(17):1388-1402
27. Li C, Hampson IN, Hampson L et al (2000) CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 14(1):55-64 (Pubitemid 30051523)
28. Leek R (2001) The prognostic role of angiogenesis in breast cancer. Anticancer Res 21(6B):4325-4331 (Pubitemid 34240962)
29. Moebus V, Jackisch C, Lueck H-J et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclo-phosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28(17):2874-2880
30. Duff SE, Li C, Garland JM et al (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17(9):984-992 (Pubitemid 36676386)
31. Dales J, Garcia S, Andrac L et al (2004) Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome. Int J Oncol 24(5):1197-1204
32. Chenggang L, Baoqiang G, Phillip BW et al (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer 89(2):122-126
33. Vo M, Evans M, Leitzel K et al (2010) Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy. Breast Cancer Res Treat 119(3):767-771
34. Beresford MJ, Harris AL, Ah-See M et al (2006) The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer 95(12): 1683-1688 (Pubitemid 44950794)
35. Warrington K, Hillarby MC, Li C et al (2005) Functional role of CD105 in TGF-β1 signalling in murine and human endothelial cells. Anticancer Res 25(3B):1851-1864 (Pubitemid 40904577)
36. Zhu Y, Sun Y, Xie L et al (2003) Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke 34(10):2483-2488 (Pubitemid 37221969)
37. Lopes N, Sousa B, Vieira D et al (2009) Vessel density assessed by endoglin expression in breast carcinomas with different expression profiles. Histopathology 55(5):594-599
38. Escorcia FE, Henke E, McDevitt MR et al (2010) Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 70(22):9277-9286
39. Drevs J, Müller-Driver R, Wittig C et al (2002) PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62(14):4015-4022 (Pubitemid 34791068)
40. Nam J-S, Terabe M, Mamura M et al (2008) An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68(10): 3835-3843
41. She X, Matsuno F, Harada N et al (2004) Synergy between antiendoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer 108(2):251-257 (Pubitemid 37541779)
42. Uneda S, Toi H, Tsujie T et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125:1446-1453
43. Lee S-H, Mizutani N, Mizutani M et al (2006) Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother 55(12):1565-1574 (Pubitemid 44327844)
44. O'Shaughnessy J, Miles D, Gray RJ et al (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28(suppl 15):1005 meeting abstracts
45. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275-1281